Source comparison
TB-500 vs Stem Cell Therapy: Feature-by-Feature Breakdown
Primary Mechanism Actin regulation, VEGF upregulation, cell migration Cellular differentiation, engraftment, paracrine signaling TB-500 modulates existing cells; stem cells attempt replacement Administration Route Subcutaneous or intramuscular injection Direct
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Actin regulation, VEGF upregulation, cell migration
- Cellular differentiation, engraftment, paracrine signaling
- TB-500 modulates existing cells; stem cells attempt replacement
- Administration Route
- Subcutaneous or intramuscular injection
- Direct injection into target tissue (intra-articular, IV, local)
- TB-500 is systemic; stem cells require precise placement
- Regulatory Status (U.S.)
- Research use only. No FDA approval
- Approved for blood disorders; investigational for regenerative use
- Both lack FDA approval for most regenerative applications
- Evidence Quality
- Strong preclinical data; limited human trials
- Moderate clinical trial data; inconsistent structural outcomes
- Neither has robust Phase III human evidence for tissue regeneration
- Engraftment Requirement
- Not applicable. No cells introduced
- Critical. Most injected cells die within 72 hours
- Stem cell survival rates remain the primary limitation
- Cost (Investigational Use)
- $200–$800 per treatment cycle
- $3,000–$15,000 per treatment depending on cell source and prep
- Stem cell therapy is 10–20× more expensive